104 related articles for article (PubMed ID: 32585151)
1. Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.
Zhao X; Bao M; Zhang F; Wang W
Exp Cell Res; 2020 Sep; 394(2):112148. PubMed ID: 32585151
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA DLEU1 aggravates osteosarcoma carcinogenesis via regulating the miR-671-5p/DDX5 axis.
Chen X; Zhang C; Wang X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3322-3328. PubMed ID: 31379208
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
Ando K; Shah AK; Sachdev V; Kleinstiver BP; Taylor-Parker J; Welch MM; Hu Y; Salgia R; White FM; Parvin JD; Ozonoff A; Rameh LE; Joung JK; Bharti AK
Oncotarget; 2017 Jul; 8(27):43733-43751. PubMed ID: 28415827
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells.
Hollomon MG; Gordon N; Santiago-O'Farrill JM; Kleinerman ES
BMC Cancer; 2013 Oct; 13():500. PubMed ID: 24160177
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
6. DDX5 is a multifunctional co-activator of steroid hormone receptors.
Wagner M; Rid R; Maier CJ; Maier RH; Laimer M; Hintner H; Bauer JW; Onder K
Mol Cell Endocrinol; 2012 Sep; 361(1-2):80-91. PubMed ID: 22476084
[TBL] [Abstract][Full Text] [Related]
7. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway.
Du C; Li DQ; Li N; Chen L; Li SS; Yang Y; Hou MX; Xie MJ; Zheng ZD
Sci Rep; 2017 Feb; 7():42876. PubMed ID: 28216662
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
Lourda M; Trougakos IP; Gonos ES
Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.
Taniguchi T; Iizumi Y; Watanabe M; Masuda M; Morita M; Aono Y; Toriyama S; Oishi M; Goi W; Sakai T
Cell Death Dis; 2016 May; 7(5):e2211. PubMed ID: 27148684
[TBL] [Abstract][Full Text] [Related]
10. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Miyaki Y; Suzuki K; Koizumi K; Kato T; Saito M; Kamiyama H; Maeda T; Shibata K; Shiya N; Konishi F
Int J Oncol; 2012 Jan; 40(1):217-26. PubMed ID: 21901246
[TBL] [Abstract][Full Text] [Related]
11. Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells.
Kumar C; Vats K; Lohar SP; Korde A; Samuel G
Cancer Biother Radiopharm; 2014 Oct; 29(8):317-22. PubMed ID: 25226352
[TBL] [Abstract][Full Text] [Related]
12. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
13. Resolution of R-loops by topoisomerase III-β (TOP3B) in coordination with the DEAD-box helicase DDX5.
Saha S; Yang X; Huang SN; Agama K; Baechler SA; Sun Y; Zhang H; Saha LK; Su S; Jenkins LM; Wang W; Pommier Y
Cell Rep; 2022 Jul; 40(2):111067. PubMed ID: 35830799
[TBL] [Abstract][Full Text] [Related]
14. DEAD-Box Helicase 5 Interacts With Transcription Factor 12 and Promotes the Progression of Osteosarcoma by Stimulating Cell Cycle Progression.
Chen Y; Wang Q; Wang Q; Liu J; Jiang X; Zhang Y; Liu Y; Zhou F; Liu H
Front Pharmacol; 2018; 9():1558. PubMed ID: 30733679
[TBL] [Abstract][Full Text] [Related]
15. The DEAD-box RNA helicase DDX3 interacts with DDX5, co-localizes with it in the cytoplasm during the G2/M phase of the cycle, and affects its shuttling during mRNP export.
Choi YJ; Lee SG
J Cell Biochem; 2012 Mar; 113(3):985-96. PubMed ID: 22034099
[TBL] [Abstract][Full Text] [Related]
16. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway.
Xue Y; Jia X; Li L; Dong X; Ling J; Yuan J; Li Q
Biochem Biophys Res Commun; 2018 Sep; 503(4):2885-2891. PubMed ID: 30119889
[TBL] [Abstract][Full Text] [Related]
17. Analysis of common gene expression patterns in four human tumor cell lines exposed to camptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways.
Guo X; Zhang J; Fu X; Wei Q; Lu Y; Li Y; Yin G; Mao Y; Xie Y; Rui Y; Ying K
Front Biosci; 2006 May; 11():1924-31. PubMed ID: 16368568
[TBL] [Abstract][Full Text] [Related]
18. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Shamanna RA; Lu H; Croteau DL; Arora A; Agarwal D; Ball G; Aleskandarany MA; Ellis IO; Pommier Y; Madhusudan S; Bohr VA
Oncotarget; 2016 Mar; 7(12):13269-84. PubMed ID: 26959889
[TBL] [Abstract][Full Text] [Related]
20. C1orf109L binding DHX9 promotes DNA damage depended on the R-loop accumulation and enhances camptothecin chemosensitivity.
Dou P; Li Y; Sun H; Xie W; Zhang X; Zhang X; Zhang D; Qiao S; Ci Y; Nie H; Han F; Li Y
Cell Prolif; 2020 Sep; 53(9):e12875. PubMed ID: 32761833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
